Graham Capital Management L.P. Has $2.20 Million Position in Blueprint Medicines Co. (NASDAQ:BPMC)

Graham Capital Management L.P. boosted its position in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 48.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,260 shares of the biotechnology company's stock after buying an additional 8,283 shares during the quarter. Graham Capital Management L.P.'s holdings in Blueprint Medicines were worth $2,203,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the company. Torray Investment Partners LLC increased its stake in Blueprint Medicines by 1.1% in the fourth quarter. Torray Investment Partners LLC now owns 16,499 shares of the biotechnology company's stock valued at $1,439,000 after acquiring an additional 186 shares during the period. Franklin Resources Inc. grew its stake in shares of Blueprint Medicines by 0.7% in the 3rd quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company's stock valued at $3,259,000 after purchasing an additional 265 shares during the period. Summit Investment Advisors Inc. raised its holdings in shares of Blueprint Medicines by 4.4% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,652 shares of the biotechnology company's stock worth $580,000 after buying an additional 283 shares in the last quarter. Pitcairn Co. lifted its position in shares of Blueprint Medicines by 2.8% during the 4th quarter. Pitcairn Co. now owns 10,608 shares of the biotechnology company's stock worth $925,000 after buying an additional 293 shares during the period. Finally, Hillsdale Investment Management Inc. boosted its stake in Blueprint Medicines by 0.6% in the 4th quarter. Hillsdale Investment Management Inc. now owns 50,830 shares of the biotechnology company's stock valued at $4,433,000 after buying an additional 310 shares in the last quarter.

Analyst Upgrades and Downgrades

BPMC has been the subject of several recent analyst reports. Needham & Company LLC dropped their price objective on Blueprint Medicines from $133.00 to $130.00 and set a "buy" rating for the company in a research note on Monday, April 28th. JMP Securities reiterated a "market outperform" rating and set a $125.00 target price on shares of Blueprint Medicines in a research report on Friday, February 14th. JPMorgan Chase & Co. boosted their price target on shares of Blueprint Medicines from $126.00 to $129.00 and gave the company an "overweight" rating in a research report on Tuesday, February 4th. Jefferies Financial Group assumed coverage on shares of Blueprint Medicines in a research note on Monday, March 17th. They set a "buy" rating and a $135.00 price objective on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and set a $135.00 price objective on shares of Blueprint Medicines in a report on Friday, May 2nd. Five investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $126.56.

Insider Buying and Selling at Blueprint Medicines

In other Blueprint Medicines news, COO Christina Rossi sold 2,274 shares of the company's stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $95.02, for a total value of $216,075.48. Following the completion of the sale, the chief operating officer now owns 69,266 shares of the company's stock, valued at approximately $6,581,655.32. This represents a 3.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ariel Hurley sold 3,203 shares of Blueprint Medicines stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $92.62, for a total transaction of $296,661.86. Following the transaction, the insider now directly owns 18,270 shares in the company, valued at approximately $1,692,167.40. This represents a 14.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,503 shares of company stock worth $1,027,931. Insiders own 4.21% of the company's stock.

Blueprint Medicines Trading Up 2.0%

NASDAQ:BPMC traded up $1.98 on Thursday, hitting $99.49. 441,060 shares of the stock were exchanged, compared to its average volume of 779,383. The stock has a market capitalization of $6.43 billion, a price-to-earnings ratio of -92.12 and a beta of 0.83. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85. Blueprint Medicines Co. has a 52 week low of $73.04 and a 52 week high of $121.90. The company's 50-day moving average price is $89.12 and its 200 day moving average price is $94.07.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.32). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. The business had revenue of $149.41 million for the quarter, compared to the consensus estimate of $158.31 million. During the same period last year, the firm earned $1.40 earnings per share. The company's quarterly revenue was up 55.5% on a year-over-year basis. On average, equities research analysts forecast that Blueprint Medicines Co. will post -1.28 earnings per share for the current year.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.